Lorvotuzumab mertansine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lorvotuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD56
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 NYesY (what is this?)  (verify)

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)

Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).[1][2]

It has been granted Orphan drug status for Merkel cell carcinoma.[3]

It has reported encouraging Phase II results for small-cell lung cancer.[4]

References[edit]